

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2410)*

INSIDE INFORMATION

ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION OF THE COMPANY

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”).

Reference is made to the announcement (the “**Announcement**”) of the Company dated June 6, 2025 in relation to the application to the CSRC (the “**CSRC Filing**”) for the H Share Full Circulation by the Company. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the CSRC recently issued a filing notice to the Company (the “**Filing Notice**”) in respect of the H Share Full Circulation. According to the Filing Notice, the CSRC Filing in relation to the H Share Full Circulation, in respect of the conversion of 4,608,000 Unlisted Shares held by one shareholder of the Company into 4,608,000 H Shares has been completed. Upon completion of such conversion and listing approval granted by the Stock Exchange, such 4,608,000 H Shares will be listed and traded on the Main Board of the Stock Exchange. The Filing Notice will be valid for 12 months from the date of approval by the CSRC. Please refer to the Announcement for details of the name of the shareholder and number of Unlisted Shares for conversion under the H Share Full Circulation plan.

As at the date of this announcement, the details of the implementation plan of the H Share Full Circulation have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation in compliance with the requirements under the Listing Rules and/or the Inside Information Provisions as and when appropriate.

The H Share Full Circulation is subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board

TYK Medicines, Inc

(浙江同源康醫藥股份有限公司)

Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, January 23, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.